237 related articles for article (PubMed ID: 15615255)
1. Economics of pathogen inactivation technology for platelet concentrates in Japan.
Staginnus U; Corash L
Int J Hematol; 2004 Nov; 80(4):317-24. PubMed ID: 15615255
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States.
Bell CE; Botteman MF; Gao X; Weissfeld JL; Postma MJ; Pashos CL; Triulzi D; Staginnus U
Clin Ther; 2003 Sep; 25(9):2464-86. PubMed ID: 14604745
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands.
Postma MJ; van Hulst M; De Wolf JT; Botteman M; Staginnus U
Transfus Med; 2005 Oct; 15(5):379-87. PubMed ID: 16202052
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the economic value of the INTERCEPT blood system in Belgium.
Moeremans K; Warie H; Annemans L
Transfus Med; 2006 Feb; 16(1):17-30. PubMed ID: 16480436
[TBL] [Abstract][Full Text] [Related]
5. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
Seghatchian J; Hervig T; Putter JS
Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
[TBL] [Abstract][Full Text] [Related]
6. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
Corash L
Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
[TBL] [Abstract][Full Text] [Related]
7. Infectious risks associated with the transfusion of blood components and pathogen inactivation in Japan.
Satake M
Int J Hematol; 2004 Nov; 80(4):306-10. PubMed ID: 15615253
[TBL] [Abstract][Full Text] [Related]
8. Pathogen inactivation: emerging indications.
Kleinman S
Curr Opin Hematol; 2015 Nov; 22(6):547-53. PubMed ID: 26390164
[TBL] [Abstract][Full Text] [Related]
9. Approaches to minimize infection risk in blood banking and transfusion practice.
Lindholm PF; Annen K; Ramsey G
Infect Disord Drug Targets; 2011 Feb; 11(1):45-56. PubMed ID: 21303341
[TBL] [Abstract][Full Text] [Related]
10. The rationale for pathogen-inactivation treatment of blood components.
Barbara JA
Int J Hematol; 2004 Nov; 80(4):311-6. PubMed ID: 15615254
[TBL] [Abstract][Full Text] [Related]
11. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
12. Current debate on pathogen inactivation of platelet concentrates--to use or not to use?
Hervig T; Seghatchian J; Apelseth TO
Transfus Apher Sci; 2010 Dec; 43(3):411-414. PubMed ID: 21075686
[TBL] [Abstract][Full Text] [Related]
13. Financial analysis of large-volume delayed sampling to reduce bacterial contamination of platelets.
Kacker S; Katz LM; Ness PM; Bloch EM; Goel R; Gehrie EA; Lokhandwala PM; Tobian AAR
Transfusion; 2020 May; 60(5):997-1002. PubMed ID: 32275069
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates.
Corash L
Vox Sang; 1998; 74 Suppl 2():173-6. PubMed ID: 9704443
[TBL] [Abstract][Full Text] [Related]
15. [Bacterial contamination: should it be detected or inactivated?].
Cazenave JP
Transfus Clin Biol; 2007 May; 14(1):81-5. PubMed ID: 17521943
[TBL] [Abstract][Full Text] [Related]
16. Progress toward a pathogen-free blood supply.
McCullough J
Clin Infect Dis; 2003 Jul; 37(1):88-95. PubMed ID: 12830413
[TBL] [Abstract][Full Text] [Related]
17. Current risks of transfusion-transmitted agents: a review.
Stramer SL
Arch Pathol Lab Med; 2007 May; 131(5):702-7. PubMed ID: 17488155
[TBL] [Abstract][Full Text] [Related]
18. Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model.
Prioli KM; Karp JK; Lyons NM; Chrebtow V; Herman JH; Pizzi LT
Appl Health Econ Health Policy; 2018 Dec; 16(6):889-899. PubMed ID: 30062464
[TBL] [Abstract][Full Text] [Related]
19. Safety of the blood supply.
Sloand EM; Pitt E; Klein HG
JAMA; 1995 Nov; 274(17):1368-73. PubMed ID: 7563562
[No Abstract] [Full Text] [Related]
20. Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system.
Cicchetti A; Coretti S; Sacco F; Rebulla P; Fiore A; Rumi F; Di Bidino R; Urbina LI; Refolo P; Sacchini D; Spagnolo AG; Midolo E; Marano G; Farina B; Pati I; Veropalumbo E; Pupella S; Liumbruno GM
Blood Transfus; 2018 Nov; 16(6):483-489. PubMed ID: 30201081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
